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targeting, 3D tumoral tissue model. 
 
ABSTRACT 
The high density of the extracellular matrix in solid tumors is an important obstacle to 
nanocarriers for reaching deep tumor regions and has severely limited the efficacy of 
administrated nanotherapeutics. The use of proteolytic enzymes prior to nanoparticle 
administration or directly attached to the nanocarrier surface has been proposed to enhance their 
penetration, but the low in vivo stability of these macromolecules compromises their efficacy and 
strongly limits their application. Herein, we have designed a multifunctional nanocarrier able to 
transport cytotoxic drugs to deep areas of solid tumors and once there, to be engulfed by tumoral 
cells causing their destruction. This system is based on mesoporous silica nanocarriers 
encapsulated within supported lipid bilayers (SLB). The SLB avoids premature release of the 
housed drug while providing high colloidal stability and an easy to functionalize surface. The 
tumor penetration property is provided by attachment of engineered polymeric nanocapsules that 
transport and controllably unveil and release the proteolytic enzymes that in turn digest the 
extracellular matrix, facilitating the nanocarrier diffusion through the matrix. Additionally, 
targeting properties were endowed by conjugating an antibody specific to the investigated 
tumoral cells to enhance binding, internalization, and drug delivery. This multifunctional design 
improves the therapeutic efficacy of the transported drug as a consequence of its more 
homogeneous distribution throughout the tumoral tissue.  
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INTRODUCTION 
Despite huge research efforts carried out in the last decades, cancer continues to be one of the 
leading causes of mortality worldwide.
1
 Cancer cannot be considered as one simple disease. 
There are many different types of cancer depending on the type of malignant cell and the 
affected organ and even patient specific heterogeneity. Therefore, each of them presents its own 
set of particular features and therapeutic challenges. Moreover, even within the same tumor type, 
usually coexists in multiple tumor clonal cell populations with different genetic alterations which 
respond differently to the common administered therapeutic agents.
2
 When it is not possible to 
remove the tumoral mass by surgery, the common treatment involves the administration of high 
energy radiation (radiotherapy) and/or the use of potent cytotoxic compounds (chemotherapy) in 
order to destroy dividing cells. However, the lack of selectivity of these therapies causes severe 
systemic toxicity on surrounding healthy tissues compromising not only the efficacy of the 
therapy but also the patient´s life or quality of life. Since Maeda and Matsumura´s discovery in 
1986 of passive accumulation of nanoparticles within tumoral masses,
3
 the use of nanoparticles 
as drug carriers has been extensively studied in oncology.
4
 This phenomenon, referred to as the 
Enhanced Permeation and Retention effect (EPR), is caused by the unique blood vessel 
architecture present in solid tumors that presents pores with diameters up to a few hundred 
nanometers.
5
 Thus, when nanoparticles reach the tumoral area, they are extravasated into the 
tumor passing through these pores, whereas they cannot cross the healthy blood vessel walls. The 
discovery of the EPR effect triggered the development of a multitude of nanocarriers with the 
aim to deliver the cytotoxic compounds directly to the diseased zone, without affecting the rest 
of the healthy tissues.
6
 These nanodevices have been engineered to possess remarkable 
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properties such as stimuli-responsive drug release,
7
 invisibility to the immune system,
8
 capacity 
to recognize the tumoral cells
9
 or even target to the tumor stem cells.
10
 However, the clinical 
application of nanocarriers is still far from being a reality. A recent meta-study concluded that 
only 0.7% of the administered nanoparticles accumulate in the tumoral tissue which could 
explain the low effectiveness of the nanotherapies observed in clinical trials.
11
 One common 
problem in  nanomedicine,  is the lack of system penetration into the tumoral tissue.
12
 The 
extracellular matrix of tumoral tissues has usually a denser extracellular matrix than their healthy 
counterparts due to the higher presence of collagen which limits the penetration of carriers into 
the tissue..
13
 Thus, the extravasated nanomedicine accumulates mainly on the periphery of the 
tumor where it can be easily flushed out of the tumor by intravasation after causing only local 
peripheral effects. The intratumoral administration of proteolytic enzymes such as collagenase or 
hyaluronidase prior to nanoparticle injection has been proposed to enhance the particle 
penetration.
14
 These proteolytic enzymes have also been anchored on the nanocarrier surface 
resulting in improved particle penetration.
15
 Recently, Villegas et al. reported the use of pH-
responsive polymeric nanocapsules which contains collagenase for enhancing the particle 
penetration in 3D tumoral tissue models while protecting the proteolytic enzyme.
16
 These 
nanocapsules were rapidly hydrolyzed under mild acidic conditions expected within hypoxic 
tumor tissue. In the mild acidic environment, the housed enzymes are released in two hours, 
whereas nanocapsule hydrolysis requires longer times under normal physiological conditions. In 
addition to achieving higher penetration within the tumoral mass, an efficient nanocarrier should 
be able to fulfill other features such as the ability to selectively bind to the target tumoral cell 
within a myriad of different cell populations and retain the transported therapeutic payload until 
it reaches the intracellular space of the malignant cell.
17
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Herein, we report the synthesis and evaluation of a novel multifunctional nanocarrier able to 
penetrate deeply within a solid tumoral mass while retaining their payload and selectively bind 
and internalize into tumor cells where the triggered release of the cytotoxic cargo leads to 
destruction of the targeted tumor cell. This nanodevice is composed of a mesoporous silica 
nanoparticle (MSN) capable of loading high amounts of drugs due to its very high specific area 
and accessible interior pore volume. The MSN external surface is encapsulated within a 
supported lipid bilayer conjugated with proteolytic NPs, targeting ligands, and PEG in a 
nanocarrier construct referred to as a protocell.
18,19
 
The protocell SLB serves to protect and retain cargo within the MSN until pH triggered release 
within acidified endosomal environments.
19
 It also confers unique properties to the system such 
as high colloidal stability, low immunogenicity and long circulation times within the blood 
stream. The SLB of the protocell was decorated with pH-responsive collagenase nanocapsules 
for enhancing tissue penetration and with EGFR-antibodies, able to selectively bind to cells that 
overexpress epidermal growth factor receptors (EGFR), in order to increase the internalization of 
the protocell into tumoral cells and ensuing drug delivery. The capacity of this novel 
multifunctional protocell to recognize EGFR-positive tumoral cells which are deeply located 
within a solid tumoral mass was tested employing an in vitro 3D cell culture model, showing 
significantly improved penetration, internalization and destruction capacity of the malignant cells 
relative to protocells prepared without collagenase nanocapsules. 
RESULTS 
2.1. Synthesis of Protocells 
The protocell MSN core was designed with hexagonally arranged cylindrical pores of diameter 
3-4-nm, which represents the optimal size for loading therapeutic agents based on small 
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molecules,
20,21
 as is the case for many conventional cytotoxic compounds employed in 
antitumoral chemotherapy.
22
 MSNs were synthesized following a modified Stöber method 
reported elsewhere,
23
 yielding monodisperse nanoparticles with an average diameter of 75-100 
nm according to dynamic light scattering (DLS) measurements (Figure S1) and transmission 
electron microscopy (TEM) (Figure 1a). MSNs were covalently labeled with rhodamine B 
throughout the silica matrix to enable fluorescence imaging.  
  
 
Figure 1.  TEM images of a) MSN, b) PC-COOH13, c) Colnc and d) PC-COOH13-Colnc. 
MSNs were encapsulated within SLBs formed by fusion of zwitterionic lipid-based vesicles 
(Scheme 1). The zwitterionic lipid, 1,3-distearoyl-sn-glycero-3-phosphocholine (DSPC) was 
chosen as the main component in order to provide structural support to the liposome and 
Page 6 of 32
ACS Paragon Plus Environment
Chemistry of Materials
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 7
cholesterol was added for controlling the fluidity of the SLB. In order to provide anchoring 
points for the further introduction of  targeting moieties and collagenase nanocapsules, the 
functional PEGylated lipids, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000] (DSPE- PEG(2000)-COOH) providing a functional  
carboxylic group and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-2000] (DSPE-PEG(2000)-NH2), providing a functional amine, were also employed in the 
vesicle formulation. Here the polyethylene glycol chain (2000 Da) intercalated between the 
phospholipid head group and the respective functional group serves to enhance the colloidal 
stability of the resulting vesicle, as well as the protocells once formed. Moreover, it is well-
established that the presence of PEG chains on the particle surface improves the circulation time 
of the nanocarriers within the blood stream.
25
 These polymeric chains hamper the adsorption of 
the immune proteins (opsonins) responsible for labeling foreign bodies for macrophage capture. 
Liposomes were synthesized following the thin-film hydration or Bangham method.
26
 This 
method is based on the dissolution of various phospholipids in one organic phase followed by 
solvent evaporation, obtaining a lipid film. After that, the film is hydrated in a salt-rich aqueous 
medium under strong sonication which results in the liposome formation. Two batches of 
vesicles were synthesized maintaining a fixed molar ratio of cholesterol to DSPE-PEG(2000)-
NH2 (20:2) and varying the molar ratio of DSPC and DSPE-PEG(2000)-COOH (65:13) and 
(48:30), respectively. The percentage of introduced amino groups was kept constant at 2%, 
because this percentage is sufficient for the antibody attachment as previously reported.
18
 Thus, 
the two batches present different concentrations of carboxylic groups in order to determine the 
effect of the concentration of collagenase nanocapsules on penetration. Both vesicle batches 
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were extruded to yield a monodisperse size distribution centered at 100 nm according to DLS 
measurements (DLS of DSPE-PEG(2000)-COOH (65:13) shows in Figure S2 as an example). 
 
 
 
Scheme 1. Synthetic pathway for the production of protocells. 
Two batches of protocells were prepared by incubating an aqueous suspension of MSN with 
vesicles of the respective formulation under strong sonication for 20 seconds in phosphate 
buffered saline (PBS). Excess vesicles not fused to the silica surface were removed via 
centrifugation. Both protocell batches (PC-COOH13 and PC-COOH30, respectively) showed 
monodisperse sizes centered around 175 nm according to the DLS measurements (Figure S3). 
The presence of the lipid bilayer on the MSN surface was confirmed by TEM using 
phosphotungstic acid (PTA) as a staining agent (Figure 1b).
26
 The thickness of the supported 
lipid bilayer was measured to be ~4.7 nm on both batches (n = 20), which is in agreement with 
the values reported in the literature for ’protocell’ systems.
18
  
 
 
2.2. Synthesis of Collagenase Nanocapsules (Colnc) 
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As was mentioned in the introduction, tumor penetration is one of the most important 
challenges facing the field of nanomedicine. The diffusion of nanometric objects in a fluid is 
understood by the Stokes-Einstein equation (D = KT/6πηr) which indicates that the diffusion rate 
(D) is inversely proportional to the particle radius (r) and also to the viscosity of the media (η). 
Therefore, the diffusion of nanometric objects is clearly reduced by increasing particle size and 
the viscosity of the media. Many solid tumors exhibit overproduction of collagen, which 
accumulates within the extracellular matrix (ECM) and greatly impedes particle diffusion 
through the inner tumoral core. The intratumoral injection of proteolytic enzymes able to destroy 
these collagen accumulations partially alleviates this problem, but due to the labile nature of 
these enzymes, it is necessary to administer several dosages of them in order to achieve 
significant results. Our research group has reported the use of polymeric nanocapsules which 
contain enzymes encapsulated within an organic shell in order to preserve their catalytic function 
in the presence of aggressive agents such as temperature or other proteolytic enzymes.
27,28 
Recently, collagenase has been encapsulated within pH-sensitive polymeric nanocapsules which 
were designed to rapidly release the housed enzyme when the pH drops to the mild acidic 
conditions usually present in many tumoral tissues but retains the enzyme trapped within the 
polymeric matrix up to 24 hours under normal physiological conditions.
16
 Following the same 
methodology, collagenase polymeric nanocapsules were formed by a radical polymerization 
method which employs acrylamide (AA), as the main structural monomer, 2-
aminoethylmethacrylate (Am) as the monomer that provides amino groups required for the 
further attachment on the protocell surface, and ethylenglycol dimethacrylate (EG) as pH-
degradable cross-linker (Scheme 2). In this process, monomer/protein molar ratio of 2419:1 and 
AA:Am:EG ratio (7:6:2) were employed. 
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The resulting nanocapsules were characterized by DLS measurements and TEM showing an 
average diameter of about 50 nm and a round-shaped morphology (Figure 1c). The employed 
polymer composition was selected in order to exhibit degradation by progressive hydrolysis over 
24 hours, which is accelerated in the mild-acidic conditions present in the tumor environment. 
The nanocapsule degradation at physiological pH was monitored by following decrease in 
hydrodynamic diameter over time. We observed that the collagenase nanocapsules initially of 
~50-nm in hydrodynamic diameter, were progressively degraded until they reached a size of ~7 
nm, indicating the enzymes complete release after 24 hours (Figure S4). The encapsulated 
collagenase retained its catalytic activity as was previously reported.
16
 
 
2.3. Protocell functionalization: Anchoring of anti-EGFR and collagenase nanocapsules. 
In order to confer selectivity against tumoral cells, the nanoparticle surface was decorated with 
targeting moieties capable of being specifically recognized by cell membrane receptors 
overexpressed on the surface of cancerous cells. An EGFR antibody (anti-EGFR) was selected as 
a targeting ligand due to the common overexpression of EGFR in many human cancers, in 
particular lung cancer.
30,31
 For this reason, A549 lung tumor cells were selected in this work as a 
cellular tumoral model. The anchoring of anti-EGFR and collagenase nanocapsules was carried 
out following a multi-step synthetic process (Scheme 2).  
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Scheme 2. Synthesis of Colnc (upper scheme) and attachment pathway of Colnc and Anti-EGFR-
biotin on PC surface (lower scheme). 
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The first step (i) was the conversion of the amino groups present on the protocell surface into 
thiol groups by the reaction with 2-iminothiolane hydrochloride (Traut’s reagent). Then, these 
thiol groups were employed to anchor the maleimide-neutravidin moieties (ii). Thus, the 
protocells were ready for the antibody introduction employing biotinylated-Anti-EGFR (iv or v). 
Due to the sensitive nature of antibodies, collagenase nanocapsules were anchored (iii) prior to 
the introduction of antibody in order to preserve the recognition capacity of this macromolecule. 
As was mentioned above, two protocell batches displaying different percentages of carboxylic 
groups were synthesized (PC-COOH13 and PC-COOH30) in order to find the optimal 
composition which resulted in a higher collagenase nanocapsule attachment. Thus, collagenase 
nanocapsules were anchored on both types of protocells, using well-known carbodiimide 
chemistry (iii). The presence of collagenase nanocapsules was confirmed by measuring the 
enzymatic activity of the PC-COOH13-Colnc and PC-COOH30-Colnc respectively, using 
EnChekGelatinase/Collagenase Assay Kit. Both samples exhibited similar enzymatic activity 
and therefore, an increase in the amount of carboxylic groups on the PC surface did not improve 
the Colnc attachment (Figure S5). Additionally, the colloidal stability of PC-COOH13-Colnc was 
significantly higher than PC-COOH30-Colnc, showing that the particles remained well suspended 
in PBS for more than 15 days. For these reasons, PC-COOH13-Colnc was selected as the best 
system for the further attachment of Anti-EGFR which was carried out through the formation of 
a biotin-neutravidin bridge (iv and v). 
 
2.4. In vitro Evaluation of Protocell targeting capacity in 2D model  
As described above, Anti-EGFR was anchored on the protocell surface for improving the 
particle uptake within the tumoral cells. The capacity of these systems to selectively bind to 
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tumoral cells was tested by employing 2D cultures of A549 lung cancer cells, because these cells 
overexpress EGFR on their surface. A549 cells were exposed for 24 hours to a fixed 
concentration of protocells (80µg/ml) with and without the antibody anchored on their surface. 
After this time, the cells were gently washed with PBS in order to remove all non-internalized 
particles. The percentage of cells which had engulfed fluorescent nanoparticles was determined 
by flow cytometry thanks to the presence of rhodamine B covalently labeled within the silica 
matrix of the protocells (Figure 2). 
 
Figure 2. Cellular uptake of protocell with and without Anti-EGFR and Colnc. Samples were 
performed in triplicate. 
The results confirmed the importance of the functionalization with the antibody because only 
2% of the tumoral cells engulfed the protocells that did not present the antibody on their surface, 
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whereas this value rose to over 90% when the antibody was present. In the complete system 
(Colnc-PC-Anti-EGFR), collagenase nanocapsules were anchored prior to the antibody 
functionalization. This anchoring process requires carboxylic acid activation by carbodiimide 
chemistry, which could alter the neutravidin pockets due to the presence of carboxylic and amine 
groups in this protein and therefore could compromise the antibody conjugation. In order to 
evaluate this possibility, the cells were exposed to Colnc-PC-Anti-EGFR and compared to the 
PC-Anti-EGFR alone.  Both the full construct, Colnc-PC-Anti-EGFR, and PC-Anti-EGFR 
yielded similar uptake of 85% and >90% respectively, confirming the suitability of this strategy 
for the synthesis of the complete nanodevice. 
2.5. Evaluation of penetration capacity in 3D tumoral tissue model 
In order to evaluate the penetration capacity of these multifunctional protocells, a 3D tissue 
model which mimics the existing conditions in a solid tumoral mass was prepared. This model 
was based on the use of a 3D collagen gel containing embedded tumoral cells within its 
structure. This model presents similar consistency and rheological properties to human tumor 
tissue, and therefore, it can be employed as a simple substitute for a complex in vivo 
microenvironment.
32
 Our model consisted of a monolayer of A549 cells on which a 3D collagen 
gel with embedded tumoral cells of 200 µm thickness was grown (Figure 3). 
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Figure 3. Evaluation of penetration and internalization capacity of PC-Anti-EGFR and Colnc-
PC-Anti-EGFR nanodevices, employing 3D tumoral tissue models. Cell nuclei are stained in 
blue, actin filaments were stained in green and protocells were labeled in red (white bars 
correspond to 25 µm). Confocal fluorescent micrographs of each separate channel can be found 
in supporting information (Figure S6).  
The gel mimics the ECM of the tumor and acts as barrier hindering the diffusion of protocells 
to the A549 monolayer. Thus, to test the enhanced penetration of the system decorated with 
collagenase nanocapsules, a suspension of fluorescent protocells (80 µg/mL) bearing the 
antibody and prepared with or without collagenase nanocapsules, was carefully placed on the top 
of the gel. After 24 h of incubation, the gels were gently washed with PBS in order to remove the 
protocells which were unable to penetrate within/into the collagen matrix. The capacity to reach 
the bottom cell monolayer was assessed in each case by fluorescence confocal microscopy. The 
cell nuclei were stained with DAPI (blue) and, with the aim to assess that protocells were truly 
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engulfed within the cell cytoplasm thanks to the presence of the targeting moiety, actin filaments 
were stained with green phalloidin. The confocal images show that only protocells functionalized 
with nanocapsules were able to reach the bottom layer, as can be observed by the existence of 
perinuclear red dots which correspond to the rhodamine B labeled MSN cores of the protocells. 
This result confirms the capacity of Colnc-PC-Anti-EGFR to overcome the collagen barrier and 
reach deep layers of the tissue model. In addition, these protocells were found within the tumoral 
cell cytosol, which confirms the enhanced internalization of these nanocapsule-bearing protocells 
inside malignant cells. On the contrary, PC-Anti-EGFR were not able to overcome the collagen 
barrier and they were  likely removed in the washing step, as can be observed by the absence of 
red dots (labeled nanocapsule-free protocells) in the cell layer. 
 
2.6. Evaluation of cytotoxic capacity of drug-loaded protocells in 3D tumoral tissue model 
Having established the ability of Colnc-PC-Anti-EGFR to reach deep areas within a 3D tumoral 
model and once there, to be selectively internalized by tumoral cells, the ability of the system to 
transport and deliver cytotoxic drugs capable of inducing cell death was studied. Topotecan 
(TOP) is a potent antitumoral therapeutic but it suffers significant instability in the blood stream 
losing its activity in a few hours.
33
 For this reason, repeated dosages are required in order to 
maintain its concentration in the blood, which leads to severe side effects. It has been reported 
that the encapsulation of TOP within a nanocarrier improves its therapeutic efficacy.
34
 For these 
reasons, topotecan was selected as drug model for this system. Colnc-PC-Anti-EGFR were loaded 
prior to the formation of the protocell by incubating the silica core for 24 hours in an aqueous 
solution of topotecan (3 mg·mL
-1
). The loading capacity of the protocells was determined by 
differences in fluorescence between the topotecan solution, before and after the loading, yielding 
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0.6% (w:w) of cargo. A suspension of topotecan-loaded Colnc-PC-Anti-EGFR was deposited on 
the surface of the 3D tumoral tissue model. PC-Anti-EGFR loaded with the same amount of 
topotecan was employed as a control in order to evaluate the cytotoxic capacity of protocells 
which did not possess penetration capacity. After 24 and 48 hours of incubation time, cell 
viability was evaluated by the Alamar blue viability assay. At 24 hours, the results showed that 
topotecan-loaded Colnc-PC-Anti-EGFR induced around 40% of cell mortality, whereas the 
system which did not contain the collagenase nanocapsules had negligible cytotoxicity (Figure 
4). After 48 hours, the cytotoxicity observed in the case of topotecan(TOP)-loaded Colnc-PC-
Anti-EGFR reached up to 60% and PC-Anti-EGFR induced around 20% of cell destruction. The 
cytotoxicity provoked by this last nanodevice was probably caused by the small amount of TOP 
that leaks from protocells when they are exposed to physiological conditions over a relatively 
long timespan (Figure S7).
18
 These results confirmed that the higher penetration capacity of 
collagenase nanocapsules results in significant improvements in the therapeutic efficacy of the 
cytotoxic compounds transported by these multifunctional protocells. 
 
Figure 4. Cytotoxic capacity of Protocells in 3D tumoral tissue model after 24 hours of 
incubation (n =3, p<0.05).  
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3. Conclusions 
Herein, a multifunctional tumor-penetrating nanocarrier capable of selective delivery of 
antitumoral drugs to deep tumoral layers has been developed. This system is composed of 
mesoporous silica nanocarriers encapsulated within a supported lipid bilayer (aka protocell). The 
SLB of the protocell construct was modified with collagenase containing nanocapsules that serve 
to digest the highly dense tumoral extracellular matrix and enable protocell penetration. These 
collagenase nanocapsules were designed to protect the enzymatic activity of the collagenase until 
the target tissue is reached and then, to have pH-triggered (accelerated) release of collagenase 
within the tumoral area. Additionally, the “plug and play” feature of protocell surface allowed 
anchoring of EGFR antibodies, whose receptors are commonly overexpressed in human lung 
cancer cells, allowing a preferential internalization within tumoral cells.  Thus, the system 
achieves highly efficient penetration within dense matrix, selective internalization by tumoral 
cells and successful and controlled delivery of cytotoxic anticancer drugs.  The importance of 
this system was highlighted by employing a 3D tumoral tissue model that mimics the 
extracellular matrix present in diseased tissues. Therefore, this system has demonstrated the 
capability to overcome one of the major problems of current nanomedicine, which is the limited 
penetration of nanosystems. The application of this strategy would pave the way for the design of 
smarter nanoconstructs able to achieve more homogeneous drug distribution within solid tumors, 
which is an important advance toward their clinical applications. 
 
 
MATERIALS AND METHODS 
4.1. Materials 
Page 18 of 32
ACS Paragon Plus Environment
Chemistry of Materials
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19
Rhodamine B isothiocyanate (RBITC) (Sigma Aldrich); Ethanol (Dismadel); (3-
aminopropyl)triethoxysilane (APTES) (ABCR); Hexadecyltrimethylammonium bromide 
(CTAB) (Sigma Aldrich); ammonium hydroxide (NH4OH, 28-30%) (Fluka); Tetraethyl 
orthosilicate (TEOS) (Aldrich); Ammonium nitrate (Sigma Aldrich); 1,3-distearoyl-sn-glycero-
3-phosphocholine (DPSC) (Avanti Lipids); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG(2000)-NH2) (Avanti Lipids); 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] 
(ammonium salt) (DSPE- PEG(2000)-COOH) (Avanti Lipids); Cholesterol (Avanti Lipids); 
Traut´s reagent  (Aldrich); Maleimide activated netrAvidin (thermo Scientific); biotinlyated 
EGFR antibody (Abcam); Collagenase Type I (Life Technologies); Acrylamide (Fluka); 2-
Aminoethyl methacrylate hydrochloride (Sigma Aldrich); Ethylene glycol dimethacrylate (Sigma 
Aldrich); Ammonium persulfate (Sigma Aldrich); N,N,N’,N’-Tetramethylethylenediamine 
(Sigma Aldrich); Amicon®Ultra-2mL Centrifugal Filters Ultracel®- 10K (Millipore); N-(3- 
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (Sigma Aldrich); N-
Hydroxysuccidimide, (Sigma Aldrich);  EnChek®Gelatinase/Collagenase Assay Kit (Life 
Technologies);  10X PBS Buffer pH=7.4 (Ambion); Dulbecco’s modified eagle’s medium 
(Sigma Aldrich);  Rat tail collagen (type I) First Link (UK) Ltd;  Bovine serum Albumin (BSA) 
(Sigma); Paraformaldehyde (Sigma Aldrich); Atto488 phalloidine (Sigma Aldrich); Triton® X-
100 (Aldrich®); DAPI (Sigma®); Topotecan (Sigma Aldrich); Alamar blue (Invitrogen). 
4.2. Instrumental section  
The hydrodynamic size of mesoporous nanoparticles and protein capsules was measured by 
means of a Zetasizer Nano ZS (Malvern Instruments) equipped with a 633 nm “red” laser. 
Transmission Electron Microscopy (TEM) was carried out with a JEOL TEM 3000 instruments 
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operated at 300 kV, equipped with a CCD camera. Sample preparation was performed by 
dispersing MSN or protocells in pure ethanol or in distilled water respectively and subsequent 
deposition onto holey carbon coated copper grids. A solution of 1% of phosphotungstic acid 
(PTA) pH 7.0 was employed as staining agent in order to visualize the protein capsules alone and 
attached on the mesoporous surface. Fluorescence was measured with Synergy 4, power supply 
for Biotek Laboratory Instrument 100-240VAC, 50/60Hz, 250W. Confocal microscope Olympus 
FV1200 (Electron Microscopy Centre, UCM). 
4.3. Synthesis of Mesoporous Silica Nanoparticles (MSN) 
In order to prepare dye-labeled mesoporous silica nanoparticles, 1.5 mg of Rhodamine B 
isothiocyanate (RBITC) was dissolved in 1mL of ethanol and 1.5 µL of (3-
aminopropyl)triethoxysilane (APTES) and the solution RBITC-APTES was keep at room 
temperature under magnetic stirring for 2 h. 0.290 g of Hexadecyltrimethylammonium bromide 
(CTAB) was dissolved 150 g in ammonium hydroxide 0.32 M and the solution was incubated at 
50 
◦
C under magnetic stirring for 1 h in a 200 mL beaker sealed with parafilm. Then 3 mL of 
0.88 M Tetraethyl orthosilicate (TEOS) in ethanol and RBITC-APTES were added to the 
surfactant solution after adjusting the stirring speed to 650 rpm. The mixture was incubated at 50 
◦
C under magnetic stirring for 1 h without parafilm, then the solution was aged at 50 
◦
C overnight 
under static conditions. The next day, the particles were subjected to a hydrothermal treatment at 
70°C for 20 h before being collected by centrifugation and washed three times with water and 
ethanol. The surfactant was removed placing the particles in 500 mL of a solution of 95% 
ethanol, 5% water, and 10 g NH4NO3 mL
−1
 at 80 °C during 3 h with reflux and under stirring. 
The nanoparticles were washed with ethanol and were finally stored in pure ethanol. 
4.4. Liposome preparation 
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The lipids and cholesterol were solubilized in choloroform and were stored at -20 
◦
C. To prepare 
liposomes, the corresponding lipids were mixed at mol % ratios: DSPC/Chol/DSPE-PEG(2000)-
NH2/DSPE- PEG(2000)-COOH=65/20/2/13 and 48/20/2/30. The lipids were dried under vacuum 
to remove the organic solvent and obtain lipids film and were rehydrated in 1x PBS and bath 
sonicated for 1 h to obtain liposome solution. In order to obtain a monodispersed liposome 
solution, the liposomes were extruded using 0.05 µm polycarbonate filter membrane at least 21 
times. Then monodispersed liposomes were obtained. 
4.5. Synthesis of Protocells (PC-CO2H13 and PC-CO2H30)  
The silica nanoparticles were transferred to water at (2.5 mg/mL) from the ethanolic suspension 
by centrifugation (15000 rpm, 10 min) and resuspension in water. To each batch of MSN, a 
suspension of liposomes 8ˑ10
-6
 mol in 1.2 mL of PBS with 13% or 30% of carboxylic groups 
was added. The mixtures were sonicated for 20 s and the excess of liposomes was removed by 
centrifugation (15000 rpm, 10 min). The pelleted protocells were redispersed in PBS(1x) by 
sonication; this process was repeated two times. Finally, the protocells were stored in 1 mL of 
PBS (2.5 mg/mL). 
4.6. Synthesis of Collagenase Capsule (Colnc). Firstly, the reaction buffer NaHCO3 (0.01 M, 
pH 8.5) was deoxygenated by freeze-vacuum-N2 cycles. Then, Collagenase (3.1 × 10
−5
 mmol) 
was dissolved in the freshly deoxygenated buffer. In a separated vial, 0.035 mmol of acrylamide 
(AA), 0.030 mmol of 2- aminoethyl metacrylate hydrochloride (Am), and 0.010 mmol of 
ethylene glycol dimetacrylate (EG) were dissolved in 1 mL of deoxygenated buffer and the 
monomer solution was added to the  protein solution. This mixture was stirred at 300 rpm for 10 
min under nitrogen atmosphere at room temperature. Then, 0.013 mmol of ammonium persulfate 
and 0.02 mmol of N,N,N′,N′-tetramethyl ethylenediamine (TMDA) dissolved in 1 mL of the 
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deoxygenated buffer were added. The solution was stirred at 300 rpm for 90 min at room 
temperature under inert atmosphere. Next, the encapsulated enzyme was purified by centrifugal 
separation with 10 KDa cut-off filters (AMICON Ultra-2 mL 10 KDa) and washed three times 
with NaHCO3 buffer (0.01 M pH 8.5). The capsules of collagenase were preserved at 4 °C. 
4.7. Protocells functionalization with Anti-EGFR and Colnc  
4.7.1. Conversion of NH2 groups into SH groups, 125 µL of 250 mM Traut´s reagent in PBS was 
added to the protocells. The reaction was kept for 2 h under stirring at room temperature. After 
this time, the excess of Traut´s reagent was removed via centrifugation (15000 rpm, 10 min) and 
the pellet of protocells was resuspended in PBS. This step was repeated twice. Finally, the thiol-
functionalized protocells were stored in 1 mL of PBS (2.5 mg·mL
-1
). 
4.7.2. Attachment of NeutrAvidin: 0.5 mL of (1 mg·mL
-1
 in water) maleimide-functionalized 
NeutrAvidin protein was added to 1 mL (2.5 mg·mL
-1
) of thiol-functionalized protocells. The 
reaction was incubated under stirring at room temperature during 12 hours. After this time, the 
excess of maleimide-functionalized NeutrAvidin was removed via centrifugation (15000 rpm, 10 
min) and the protocells pellet was resuspended in 1xPBS. This step was carried out twice. PC-
NeutrAvidin were stored in 1 mL of 1xPBS (2.5 mg·mL
-1
) at 4 ºC. 
4.7.3. Synthesis of Colnc-PC: the carboxylic groups of PC-NeutrAvidin (0.6 mL of 2.5 mg.mL
-1
 
in NaHCO3 buffer (0.01 M, pH 8.5)) were activated by adding 2.5 mg of N-(3-(Dimethylamino)-
propyl)-N′-ethylcarbodiimide hydrochloride (EDC), 2.5 mg of N-Hydroxysulfosuccidimide 
(NHS). In order to maintain the basic conditions, 2.5 mg of NaHCO3 was added to the mixture. 
The sample was placed in an orbital stirrer at 400 rpm during 10 min. After this time, 4 mg of 
collagenase nanocapsules were added and the mixture was stirred during 4 h. Colnc-PC-
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NeutrAvidin were collected by centrifugation and washed three times with PBS. Colnc-PC-
NeutrAvidin were stored at 4 °C.  
4.7.4. Synthesis of Colnc-PC-Anti-EGFR: 25 µg of biotinlyated Anti-EGFR were mixed with 250 
µg of PC-NeutrAvidin or Colnc-PC-NeutrAvidin Protocells, respectively, during 1h at room 
temperature. After this time, protocells were isolated by centrifugation (15000 rpm, 10 min) and 
they were redispersed in 250 µL of PBS(1x) yielding PC-Anti-EGFR or Colnc-PC-Anti-EGFR, 
respectively. 
4.8. Cell culture and targeting studies in 2D. Protocell selective uptake of each system were 
evaluated in 2D cell culture model and flow cytometry. For this study, 20,000 A549 cells·cm
-2
 
were seeded into each well of a 24-well plate. The cells were incubated with 80µg of the 
corresponding protocell (PC-NetrAvidin or PC-Anti-EGFR) left untreated (control) during 24 h 
at 37 °C at 5% CO2 atmospheric concentration.  Then, the cells were washed two times with 
PBS(1x) in order to remove the non-internalized protocells and then, the cells were treated with 
trypsin and the percentage of cells which have internalized fluorescence protocells were 
measured by flow cytometry using a BD FACSCaliber flow cytometer.  Samples were performed 
in triplicate and 10,000 cells were assessed per sample.  To calculate the percent of cells positive 
for the protocells, a gate was set to contain 1% of control cells.  This gate was then applied to all 
other samples to determine the percent of cells positive for protocells. 
4.9. Enzymatic Activity Measurements. The enzymatic activity of all samples were evaluated 
following the protocol EnChekGelatinase/Collagenase Assay Kit. 
4.10. Preparation of 3D tumoral tissue models based on A549-seeded collagen gels. For this 
study 20,000 A549 cells·cm
−2
 were seeded in 24-well plate. 0.5 mL of complete media was 
added to each well, and the cells were cultured at 37 °C at 5% CO2 atmospheric concentration for 
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24 h. Then, the collagen gel with A549 cells embedded into the collagen matrix was directly 
prepared in contact with the cell monolayer. For this purpose, 5.32 mL of rat tail collagen type I 
(3 mg·mL
-1
) and 15.48 mL of complete medium (Dulbecco’s modified eagle’s medium 
complemented with 10% of FBS) were mixed at 0 °C. Then, 100 µL of sodium hydroxide were 
added in order to obtain a mixture with neutral pH. 5 mL of FBS, 5 mL of complete medium and 
5 mL of a solution of cells of concentration A549 1.7 × 10
6
 cell·mL
-1
 were added to the neutral 
collagen solution, keeping the temperature at 0 °C. The mixture was pipetted into 24 well plates 
(0.25 mL per well) and incubated at 37 °C at 5% CO2 atmospheric concentration for 1 day, in 
order to promote gel formation. Then, 250 µL of complete medium was added in each well and 
the gel was incubated at 37 °C at 5% CO2 atmospheric concentration overnight. These gels were 
used for the further experiments 2 days after gel formation.  
4.11. Study of penetration and cell internalization in A549-seeded collagen gels. To study the 
penetration of nanocarriers in 3D tumoral tissue models, 80 µL of suspended PC-Anti-EGFR and 
Colnc-PC-Anti-EGFR (1 mg·mL
−1
) were respectively added on top of each gel. These samples 
were incubated at 37 °C at 5% CO2 atmospheric concentration during 24h. Then, the supernatant 
was removed and the gel was washed twice with PBS. Then, 0.5 mL of a solution 4% 
paraformaldehyde and 1% sucrose in PBS was added to each well, and were incubated for 
20min. After this time, the wells were washed two times with PBS 1x and 0.5 mL of a solution 
of 0.5% triton X-100 in PBS was added and the wells were incubated during 5 min at room 
temperature in order to permeate the cell membrane. Then, the wells were washed with PBS and 
incubated for 20 min at 37 ºC with a solution of BSA 1% in PBS. After this step, BSA was 
removed and 0.5 mL of a solution of 30 µL of ATTO488 phallloidine solution (1 mg·ml
-1
 in 
methanol) in 1 mL of BSA1%, was added. The wells were incubated for 40 min, and washed two 
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times with PBS(1x). Then, 0.5 mL of one solution of DAPI in PBS (0.1µg/mL) was added and 
the wells were incubated during15 min at room temperature. Finally, the excess of DAPI was 
removed washing two times with PBS(1x). The samples were ready for observation by 
fluorescent confocal microscopy. 
4.12. Topotecan loading 
1 mL of ethanolic suspension of MSN (2.5 mg·ml
-1
) was washed two times with water and 
finally was resupended in 0.5 ml of an aqueous solution of topotecan (5 mg·ml
-1
) during 12 
hours. The excess of topotecan was removed by centrifugation (15000 rpm, 10 min) and two 
washing steps in H2O. The amount of topotecan housed in MSN was determined by the 
difference in fluorescence in the initial cargo solution and the resulting supernatant. These 
topotecan-loaded MSN were employed for the drug-loaded protocell following the method 
described above. 
4.13. Cell Viability Studies.  
The cytotoxic capacity of these multifunctional protocells was evaluated using the same 3D 
tumoral tissue model mentioned above. Briefly, 80 µL of each drug-loaded protocell (1 
mg·mL
−1
) were added on the top of 3D gels with cells A549 embedded. These gels were 
incubated at 37 °C at 5% CO2 atmospheric concentration during 24h. The supernatant was 
removed and the gel was washed two times with PBS(1x). Then, 0.5 mL of  Alamar Blue 
solution (10%)  in cell culture medium was added  to each well and the gels were incubated at 37 
°C at 5% CO2 atmospheric concentration during 1 h. Finally, the fluorescence of supernatant was 
measured using λex = 570 nm and λem = 585 nm using a microplate reader. 
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Supporting Information. The following files are available free of charge. Hydrodynamic 
diameter of mesoporous silica nanoparticles, liposomes and protocells obtained by dynamic light 
scattering (DLS). Study of the collagenase nanocapsules hydrolysis under physiological 
condictions , enzymatic activity of different types of protocells and each separate channel of 
confocal fluorescent micrographs. 
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Multifunctional protocell capable to penetrate deep into 3D extracellular matrices and once there, 
recognize and destroy tumoral cells. 
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